An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors
NCT01413893 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35
Last updated 2017-11-21
Summary
An extension study of linifanib in subjects with advanced or metastatic solid tumors.
Conditions
Interventions
- DRUG
-
linifanib
QD daily
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Mark D. McKee, MD · Abbott
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-06-30
- Primary Completion
- 2012-06-30
- Completion
- 2012-06-30
More Related Trials
-
Phase II Sunitinib Prog Met AIPC
NCT00599313 ·Status: COMPLETED ·Phase: PHASE2
-
A Long-Term Study of Rovalpituzumab Tesirine
NCT03543358 ·Status: COMPLETED ·Phase: PHASE2
-
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
NCT00474994 ·Status: COMPLETED ·Phase: PHASE2
-
Kanitinib in Treating Patients With Advanced Solid Tumors
NCT02916095 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule
NCT01499121 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
NCT00130897 ·Status: APPROVED_FOR_MARKETING
-
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect)
NCT01014065 ·Status: COMPLETED
-
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
NCT01457118 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma
NCT00073125 ·Status: COMPLETED ·Phase: PHASE2
-
Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors
NCT00729833 ·Status: TERMINATED ·Phase: PHASE1
-
A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer
NCT00435409 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
NCT01391130 ·Status: TERMINATED ·Phase: PHASE2
-
Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases
NCT00910039 ·Status: TERMINATED ·Phase: PHASE2
-
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
NCT00890747 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
NCT01182142 ·Status: COMPLETED ·Phase: PHASE2
-
SU011248 in Advanced Hepatocellular Carcinoma
NCT00361309 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).
NCT05858749 ·Status: COMPLETED
-
A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma
NCT00515697 ·Status: COMPLETED ·Phase: PHASE2
-
Losartan + Sunitinib in Treatment of Osteosarcoma
NCT03900793 ·Status: RECRUITING ·Phase: PHASE1
-
Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line
NCT02187042 ·Status: COMPLETED
-
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
NCT02899078 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
NCT00824538 ·Status: TERMINATED ·Phase: PHASE2
-
Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
NCT00694096 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
NCT02691793 ·Status: COMPLETED ·Phase: PHASE4